Logo Logo Logo Logo Logo
  • ABOUT DROIA
  • PORTFOLIO
  • PEOPLE
  • News
  • CAREERS
  • CONTACT
  • ABOUT DROIA
  • PORTFOLIO
  • PEOPLE
  • News
  • CAREERS
  • CONTACT

QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models

Frontier Medicines and AbbVie establish global partnership to discover and develop novel therapies and E3 degraders against difficult-to-drug targets

Fierce Biotech names Accent Therapeutics as one of its “Fierce 15” biotech companies of 2020

Droia ventures

DROIA SA (LUX)  |  DROIA NV (BE)
contact@droiaventures.com

© DROIA — website made by design